A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms.

Trial Profile

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Chronic myeloid leukaemia; Essential thrombocythaemia; Leukaemia; Myeloid leukaemia; Myeloproliferative disorders; Polycythaemia vera; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Oct 2015 Results published in the Pediatric Blood and Cancer
    • 22 Oct 2014 Status changed from 'active, no longer recruiting' to 'completed' as reported by ClinicalTrials.gov record.
    • 14 Oct 2014 Planned primary completion date changed from 1 Oct 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top